Pharma BD Deal Intelligence
AstraZeneca's $443M bet on Epanova ended in a $533M full impairment and US market withdrawal after the drug's own cardiovascular outcomes trial failed in 2020 — a near-total loss.
Full analysis, sources & comparables →Epanova won FDA approval as the first free-fatty-acid omega-3, validating Omthera's CMC differentiation thesis and AstraZeneca's NDA-ready acquisition…
Independent coverage framed STRENGTH's failure as a major setback that called into question the broader omega-3 CV class — diverging sharply from the positive…
AstraZeneca terminated Phase III development and ultimately withdrew Epanova from market — closing out the Omthera acquisition thesis at a net loss versus the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AstraZeneca to acquire Omthera for $323M upfront cash + up to $120M dev/approval milestones (total $443M); added NDA-ready Epanova omega-3 dyslipidemia treatment.
AstraZeneca's $443M bet on Epanova ended in a $533M full impairment and US market withdrawal after the drug's own cardiovascular outcomes trial failed in 2020 — a near-total loss.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Omthera Pharmaceuticals Inc. (this deal) | 2013 | $443M | 16 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2013 deals · AstraZeneca PLC deals · Cardiovascular deals